Tenaya Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 12,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of $1.97 per share, which is equal to the closing price of Tenaya's common stock on November 15, 2024. Each stock option has a ten-year term and vests as follows over a total of four years: 1/4th of the original number of shares subject to the stock option shall vest on the one-year anniversary of the employee's date of hire and 1/48th of the original number of shares subject to the stock option shall vest every month thereafter, subject to such employee's continued service with Tenaya on each such date.
加利福尼亚州南旧金山，2024年11月19日（环球新闻通讯） -- Tenaya Therapeutics Inc.（纳斯达克：TNYA）是一家临床阶段的生物技术公司，旨在发现、开发和提供可能治愈的疗法，以解决心脏疾病的根本原因，今天宣布已向两名新非执行员工授予了购买总计12,000股Tenaya普通股的期权，以便于他们的入职。该期权的行使价格为每股1.97美元，这与2024年11月15日Tenaya普通股的收盘价相等。每个期权的有效期为十年，并按照如下方式在四年内逐步解锁：在员工入职一周年之际，原始数量的四分之一的股份将解锁，之后每个月将解锁原始数量的1/48的股份，前提是该员工在每个解锁日仍在Tenaya工作。
The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements, and were granted as an inducement material to each new employee's acceptance of employment with Tenaya in accordance with NASDAQ Listing Rule 5635(c)(4).
该期权受Tenaya Therapeutics Inc. 2024年诱导性股权激励计划及相关协议形式的条款和条件的约束，并作为每位新员工接受Tenaya工作的诱因，符合纳斯达克上市规则5635(c)(4)。
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit .
关于Tenaya Therapeutics
Tenaya Therapeutics股份有限公司是一家临床阶段生物技术公司，致力于发现、开发和交付有可能治愈心脏疾病根本原因的疗法。公司利用其集成且相互关联的基因治疗、细胞再生和精准医疗平台以及专有核心能力，推进了一系列新颖疗法的管线，具有多种治疗模式，以治疗罕见的遗传性心血管疾病和更常见的心脏病症。Tenaya研发的最先进的候选药物包括：TN-201，一种用于MYBPC3相关肥厚型心肌病（HCM）的基因疗法；TN-401，一种用于PKP2相关的室性心律失常性右心室心肌病（ARVC）的基因疗法；以及TN-301，一种小分子HDAC6抑制剂，最初是为保留射血分数的心衰（HFpEF）而开发的。Tenaya还有多个早期项目正在进行临床前开发。欲了解更多信息，请访问 。
Tenaya Therapeutics是一家临床阶段的生物技术公司，致力于一个大胆的使命：发现、开发和提供可能治愈的疗法，以解决心脏疾病的根本驱动因素。Tenaya拥有一套综合的内部能力，包括无特定模式的目标验证、包膜工程和制造，以生成针对稀有遗传疾病和更常见心脏疾病的基因药物组合。Tenaya的产品管线包括TN-201，一种针对MYBPC3相关肥厚型心肌病（HCM）的基因疗法；TN-401，一种针对PKP2相关心律失常右室心肌病（ARVC）的基因疗法；TN-301，一种小分子HDAC6抑制剂，旨在治疗保留射血分数的心力衰竭（HFpEF）；以及多个处于临床前开发早期阶段的项目。有关更多信息，请访问。
CONTACT: Contact
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
联系人：联系
Michelle Corral
企业传讯和投资者关系副总裁Michelle Corral：IR@tenayathera.com；Anne-Marie Fields：Annemarie.fields@precisionaq.com
IR@tenayathera.com
